Literature DB >> 31482401

MicroRNA-34a Regulates the Depression-like Behavior in Mice by Modulating the Expression of Target Genes in the Dorsal Raphè.

Luisa Lo Iacono1,2, Donald Ielpo1,3, Alessandra Accoto1, Matteo Di Segni1,2, Lucy Babicola4, Sebastian Luca D'Addario1,3, Fabio Ferlazzo1, Tiziana Pascucci1,2, Rossella Ventura5,6, Diego Andolina7,8.   

Abstract

Chronic stress exposure is known to increase vulnerability to the expression of psychiatric disorders, such as depression. Clinical and preclinical evidences support the involvement of the microRNA-34 family in stress-related psychiatric conditions and in the regulation of stress responses. However, the mechanism and the multiple targets by which the microRNA-34 family can affect the stress response and stress-related behavioral alteration are not fully known. Here, with the aid of constitutive and conditional genetic strategy, we examined the role of microRNA-34 family in the expression of depression-like phenotype in mice induced by chronic stress exposure, and we identified their "in vivo" targets during the stressful challenge. We found that microRNA-34a, under chronic stress, is significantly up-regulated in the mouse raphe nuclei, where its recruitment is necessary to induce depression-like behavioral alterations and impact the function of the serotonergic system. Moreover, by next-generation RNA-seq of Ago-2-bound mRNAs, we identified genes that are targeted by microRNA-34a in response to chronic stress and that are likely to mediate its effects.

Entities:  

Keywords:  Ago2, RISC-Seq; Chronic stress; Depression-like behavior; MicroRNA-34; Raphe nuclei; Serotonin

Mesh:

Substances:

Year:  2019        PMID: 31482401     DOI: 10.1007/s12035-019-01750-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  71 in total

1.  MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotonergic activity.

Authors:  Orna Issler; Sharon Haramati; Evan D Paul; Hiroshi Maeno; Inbal Navon; Rayya Zwang; Shosh Gil; Helen S Mayberg; Boadie W Dunlop; Andreas Menke; Rajeshwar Awatramani; Elisabeth B Binder; Evan S Deneris; Christopher A Lowry; Alon Chen
Journal:  Neuron       Date:  2014-06-19       Impact factor: 17.173

2.  Escapable and inescapable stress differentially alter extracellular levels of 5-HT in the basolateral amygdala of the rat.

Authors:  J Amat; P Matus-Amat; L R Watkins; S F Maier
Journal:  Brain Res       Date:  1998-11-23       Impact factor: 3.252

Review 3.  Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress.

Authors:  Bruce S McEwen; Lisa Eiland; Richard G Hunter; Melinda M Miller
Journal:  Neuropharmacology       Date:  2011-07-27       Impact factor: 5.250

4.  Roles of KChIP1 in the regulation of GABA-mediated transmission and behavioral anxiety.

Authors:  Kun Xia; Hui Xiong; Yeonsook Shin; Danling Wang; Tom Deerinck; Hiroto Takahashi; Mark H Ellisman; Stuart A Lipton; Gang Tong; Giannina Descalzi; Dongxian Zhang; Min Zhuo; Zhuohua Zhang
Journal:  Mol Brain       Date:  2010-08-02       Impact factor: 4.041

5.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Authors:  Gunter Meister; Markus Landthaler; Agnieszka Patkaniowska; Yair Dorsett; Grace Teng; Thomas Tuschl
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

Review 6.  Serotonin and stress coping.

Authors:  Stefano Puglisi-Allegra; Diego Andolina
Journal:  Behav Brain Res       Date:  2014-08-06       Impact factor: 3.332

7.  Preliminary comparison of plasma notch-associated microRNA-34b and -34c levels in drug naive, first episode depressed patients and healthy controls.

Authors:  Ning Sun; Lei Lei; Yanfang Wang; Chunxia Yang; Zhifen Liu; Xinrong Li; Kerang Zhang
Journal:  J Affect Disord       Date:  2016-01-14       Impact factor: 4.839

8.  ATF2, a member of the CREB/ATF family of transcription factors, in chronic stress and consequent to antidepressant treatment: animal models and human post-mortem brains.

Authors:  D Laifenfeld; R Karry; E Grauer; E Klein; D Ben-Shachar
Journal:  Neuropsychopharmacology       Date:  2004-03       Impact factor: 7.853

9.  Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder.

Authors:  Yunqiang Wan; Yuanhui Liu; Xiaobin Wang; Jiali Wu; Kezhi Liu; Jun Zhou; Li Liu; Chunxiang Zhang
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

10.  Non-coding RNA dysregulation in the amygdala region of schizophrenia patients contributes to the pathogenesis of the disease.

Authors:  Yichuan Liu; Xiao Chang; Chang-Gyu Hahn; Raquel E Gur; Patrick A M Sleiman; Hakon Hakonarson
Journal:  Transl Psychiatry       Date:  2018-02-02       Impact factor: 6.222

View more
  5 in total

Review 1.  Exploiting Circulating MicroRNAs as Biomarkers in Psychiatric Disorders.

Authors:  Bhaskar Roy; Yuta Yoshino; Lauren Allen; Kevin Prall; Grant Schell; Yogesh Dwivedi
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

Review 2.  The important roles of microRNAs in depression: new research progress and future prospects.

Authors:  Chenggui Miao; Jun Chang
Journal:  J Mol Med (Berl)       Date:  2021-02-27       Impact factor: 4.599

Review 3.  MicroRNA-dependent control of neuroplasticity in affective disorders.

Authors:  Helena Caria Martins; Gerhard Schratt
Journal:  Transl Psychiatry       Date:  2021-05-03       Impact factor: 6.222

Review 4.  The Role of MicroRNA and Microbiota in Depression and Anxiety.

Authors:  Julia M Rosa; Douglas A Formolo; Jiasui Yu; Thomas H Lee; Suk-Yu Yau
Journal:  Front Behav Neurosci       Date:  2022-03-01       Impact factor: 3.558

5.  The 24-Form Tai Chi Improves Anxiety and Depression and Upregulates miR-17-92 in Coronary Heart Disease Patients After Percutaneous Coronary Intervention.

Authors:  Jia Liu; Ping Yu; Wei Lv; Xinxin Wang
Journal:  Front Physiol       Date:  2020-03-11       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.